Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497122 | 1.00 | DDB1 (0.60) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL4832665 | 0.95 | DDB1 (0.56) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL608688 | 0.93 | PDE4B (0.53) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL29743593 | 0.93 | PDE4B (0.53) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL609655 | 0.93 | PDE4B (0.53) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL30519935 | 0.93 | PDE4B (0.53) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL610356 | 0.93 | PDE4B (0.53) | DDB1CRBNNAMPTTRPC6WNT3A | |
| SCHEMBL255448 | 0.87 | ALOX5AP (0.47) | DDB1CRBNNAMPTTRPC6KDM4E | |
| SCHEMBL29833758 | 0.87 | ALOX5AP (0.47) | DDB1CRBNNAMPTTRPC6KDM4E | |
| SCHEMBL15939963 | 0.87 | DDB1 (0.58) | DDB1CRBNNAMPTWNT3AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947811-A | Preparation method of 4- (6-aminopyridine-3-yl) piperidine-1-tert-butyl formate | 甘肃智资医药有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-112575044-B | Method for preparing key intermediate of CDK4/6 inhibitor by chemical-enzymatic method | 山东铂源药业股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114230556-B | Preparation method of CDK4/6 inhibitor intermediate | 广州安岩仁医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-114230556-A | Preparation method of CDK4/6 inhibitor intermediate | 广州安岩仁医药科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-112608299-A | Synthesis method of 4- (6-aminopyridine-3-yl) piperidine-1-tert-butyl formate | 山东铂源药业有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-112575044-A | Method for preparing CDK4/6 inhibitor key intermediate by chemical-enzymatic method | 山东铂源药业有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-107759563-B | Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate | 上海再启生物技术有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-107827869-B | Preparation method of 4- (6-aminopyridine-3-yl) piperidine-1-tert-butyl formate | 上海再启生物技术有限公司 | 2020-03-27 | — | — | CN | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| WO-2025245178-A1 | PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | INNOVO THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250026753-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| CN-118871445-A | Fused triazinone derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010117787-A2 | INHIBITING EPH B-3 KINASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| WO-2008007123-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | DDB1 1963/4885CRBN 3713/4885NAMPT 1510/4885 |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | DDB1 2133/4885CRBN 524/4885NAMPT 1555/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | DDB1 413/4885CRBN 3333/4885NAMPT 3476/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | DDB1 858/4885CRBN 3582/4885NAMPT 2290/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | DDB1 433/4885CRBN 193/4885NAMPT 3630/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | DDB1 241/4885CRBN 2274/4885NAMPT 1037/4885 |
| US-20250026753-A1 | FUSED TRIAZINONE DERIVATIVES AND METHODS OF USING THE SAME | SF3B5, RBM17, SF3A2 | DDB1 571/4885CRBN 2621/4885NAMPT 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.